[
  {
    "ts": null,
    "headline": "Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs",
    "summary": "PARSIPPANY, N.J., October 10, 2025--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.",
    "url": "https://finnhub.io/api/news?id=95952d5aabbfbcb3dcf7c984b046f712f93e4e293b1b3efab1bc372795491c52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760127300,
      "headline": "Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs",
      "id": 137049317,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "PARSIPPANY, N.J., October 10, 2025--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.",
      "url": "https://finnhub.io/api/news?id=95952d5aabbfbcb3dcf7c984b046f712f93e4e293b1b3efab1bc372795491c52"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis (ZTS): Assessing Valuation Following Dividend Announcement and FDA Nod for Dectomax-CA1 Injectable",
    "summary": "Zoetis, the world’s largest animal health company, has grabbed attention after its Board declared a fourth-quarter dividend of $0.50 per share. This move continues the firm’s long-standing streak of rewarding shareholders. See our latest analysis for Zoetis. Zoetis has seen a challenging stretch, with a 1-year total shareholder return of -23.7% and the latest share price closing at $143.39. Even as momentum has faded in recent months, the recent FDA approval for its Dectomax-CA1 Injectable...",
    "url": "https://finnhub.io/api/news?id=479d4406f0b620177b8d7d036b7a549ba12258eaf5cecadbd0748ab09a4dff40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760126712,
      "headline": "Zoetis (ZTS): Assessing Valuation Following Dividend Announcement and FDA Nod for Dectomax-CA1 Injectable",
      "id": 137049318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis, the world’s largest animal health company, has grabbed attention after its Board declared a fourth-quarter dividend of $0.50 per share. This move continues the firm’s long-standing streak of rewarding shareholders. See our latest analysis for Zoetis. Zoetis has seen a challenging stretch, with a 1-year total shareholder return of -23.7% and the latest share price closing at $143.39. Even as momentum has faded in recent months, the recent FDA approval for its Dectomax-CA1 Injectable...",
      "url": "https://finnhub.io/api/news?id=479d4406f0b620177b8d7d036b7a549ba12258eaf5cecadbd0748ab09a4dff40"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis Inc. stock outperforms competitors despite losses on the day",
    "summary": "Zoetis Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=e9c0433ff7939e875166fa1b98d77f120b9779922d7a92b591ac5f40f13e4423",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760114700,
      "headline": "Zoetis Inc. stock outperforms competitors despite losses on the day",
      "id": 137083211,
      "image": "",
      "related": "ZTS",
      "source": "MarketWatch",
      "summary": "Zoetis Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=e9c0433ff7939e875166fa1b98d77f120b9779922d7a92b591ac5f40f13e4423"
    }
  }
]